Key result
Elevated serum metalloendopeptidase identifies double diabetes with a ~0.99 diagnostic AUC.
Why the study?
To assess serum metalloendopeptidase levels in patients with double diabetes and evaluate its predictive value for diagnosis.
Does serum metalloendopeptidase level differ in patients with double diabetes compared to healthy controls?
Case-Control (n=80)
Yes
Does serum metalloendopeptidase level differ in patients with double diabetes compared to healthy controls?
Serum metalloendopeptidase is significantly elevated in patients with double diabetes and demonstrates high predictive value as a potential diagnostic biomarker.
Answers are grounded in this paper and cite their sources.
May support metalloendopeptidase as a diagnostic biomarker in double diabetes; case-control data leave open prospective validation before clinical use.
Background: Double diabetes is the term used to describe situations in which a patient exhibits characteristics that are a combination of type 1 and type 2 Diabetes Mellitus. Metalloendopeptidase or Neprilysin is membrane-bound metallopeptidase. It has a wide range of physiological function and a variety of substrates. It has a significant impact on the proteolytic functions of the kidney, cardiovascular health, immunological response, cell proliferation, and fetal development. It also has a preventative effect on the onset of type 2 diabetes, obesity, and cancer. Objective: The study aims to assess the level of MEP in patients with double diabetes and determine its predictive value in the diagnosis of double diabetes. Subjects and Methods: Eighty participants were divided into two groups for this study. 40 patients with double diabetes made up the first group (G1), whereas 40 age- and gender-matched apparently healthy subjects made up the second group (G2), which served as the control group. ELISA was used to measure the serum's metalloendopeptidase level. For the measurement of HbA1c, whole blood was used. The measurement of insulin, blood glucose, and lipid profile were performed using serum. The HOMA test measured insulin resistance. Results: This study revealed a significant elevation in serum metalloendopeptidase levels in patients with DD (p value < 0.05). The ROC curves analysis for serum metalloendopeptidase level showed the area under the curve (AUC) of serum metalloendopeptidase (pg/mL) was 0.992. Conclusions: Serum metalloendopeptidase level could be used as a novel biomarker in patients with double diabetes.
No takes yet. Share an insight, caveat, or question.
Hassan et al. (2023) conducted a case-control in Double diabetes (n=80). Double diabetes vs. Healthy controls was evaluated on Serum metalloendopeptidase level (pg/mL) (AUC 0.992, 95% CI 0.974-1.000, p=0.0001). Serum metalloendopeptidase levels were elevated in patients with double diabetes compared to healthy controls, demonstrating an AUC of 0.992 for diagnosis.
Synapse has enriched 10 related papers. Consider them for comparative context: